Table 2.

AF Incidence Rates Associated With 15 Anticancer Drugs Used as Monotherapy in Clinical Trials

Anticancer Drug	Total Summary Annualized Incidence Rates of AF Reporting, per 100 Person-Years	Summary Annualized Incidence Rates of AF Reporting Before September 2009, per 100 Person-Years	Studies Before September 2009, n	Summary Annualized Incidence Rates of AF Reporting After September 2009, per 100 Person-Years	Studies After September 2009, n	P Value for Subgroups Difference Test
Dacarbazine	0.30 (0.10-0.90)	0.14 (0.02-1.17)	3	0.39 (0.11-1.45)	8	0.43
Abiraterone	0.63 (0.34-1.17)	0.45 (0.14-1.42)	4	0.75 (0.36-1.57)	10	0.46
Clofarabine	2.38 (0.66-8.55)	1.57 (0.32-7.80)	5	7.27 (3.64-14.54)	1	0.085
Azacitidine	1.04 (0.46-2.36)	0.36 (0.14-0.97)	6	1.48 (0.55-4.00)	14	0.049
Ibrutinib	4.92 (2.91-8.31)			4.92 (2.91-8.31)	17	NA
Nilotinib	0.29 (0.15-0.58)	0.32 (0.10-1.05)	4	0.23 (0.08-0.65)	7	0.68
Ponatinib	2.35 (1.78-3.12)			2.35 (1.78-3.12)	4	NA
Midostaurin	0.65 (0.12-3.50)	0.65 (0.12-3.50)	3			NA
Ipilimumab	0.26 (0.11-0.63)	0.17 (0.03-0.92)	4	0.36 (0.14-0.93)	8	0.45
Aldesleukin	0.73 (0.21-2.52)	0.53 (0.11-2.64)	3	1.18 (0.17-8.35)	1	0.54
Lenalidomide	1.03 (0.58-1.81)	1.04 (0.57-1.92)	26	1.79 (0.33-9.64)	4	0.55
Pomalidomide	0.52 (0.22-1.23)	0.76 (0.22-2.62)	3	0.47 (0.11-2.06)	3	0.63
Rituximab	0.27 (0.15-0.49)	0.18 (0.05-0.61)	7	0.33 (0.17-0.66)	11	0.39
Bortezomib	1.33 (0.53-3.36)	1.29 (0.45-3.68)	4	1.50 (0.21-10.63)	2	0.90
Docetaxel	0.37 (0.23-0.58)	0.37 (0.19-0.70)	13	0.37 (0.19-0.71)	15	0.99

Values are incidence rate (95% CI), except as noted.

Subgroup analyses are based on publications performed before September 2009 and after September 2009 (no AF event was reported for obinutuzumab, and no study was included for anthracyclines and cisplatin).

Abbreviations as in Table 1.